Literature DB >> 11135580

Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.

A L Mellor1, J Sivakumar, P Chandler, K Smith, H Molina, D Mao, D H Munn.   

Abstract

Indoleamine 2,3 dioxygenase (IDO) activity during pregnancy protects developing fetuses from maternal immune responses in CBA mice. We show here that fetal allografts were rejected only in mating combinations where paternally inherited tissue antigens elicited potent maternal T cell responses after exposure to IDO inhibitor. IDO inhibitor treatment triggered extensive inflammation at the maternal-fetal interface in susceptible mating combinations, which was characterized by complement deposition and hemorrhagic necrosis. Identical inflammatory responses occurred in B cell-deficient (RAG-I-/-) mothers that carried a monoclonal cohort of CD8+ T cells specific for a single paternally inherited fetal major histocompatibility complex antigen. Thus, fetal allograft rejection was accompanied by a unique form of inflammation that was characterized by T cell-dependent, antibody-independent activation of complement. In contrast, no inflammation, complement deposition or T cell infiltration was elicited when mice carrying syngeneic fetuses were exposed to IDO inhibitor. These data show that IDO activity protects the fetus by suppressing T cell-driven local inflammatory responses to fetal alloantigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135580     DOI: 10.1038/83183

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  120 in total

Review 1.  Antigen-presenting cells control T cell proliferation by regulating amino acid availability.

Authors:  Aimee L Edinger; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

Review 2.  Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure?

Authors:  David A Clark
Journal:  J Assist Reprod Genet       Date:  2003-02       Impact factor: 3.412

3.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division.

Authors:  Geon Kook Lee; Hyeon Jin Park; Megan Macleod; Phillip Chandler; David H Munn; Andrew L Mellor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 4.  A noninflammatory pathway for pregnancy loss: innate immune activation?

Authors:  Jane E Salmon
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

5.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Authors:  Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast
Journal:  Cancer Immunol Immunother       Date:  2010-07-17       Impact factor: 6.968

6.  Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior.

Authors:  Jason C O'Connor; Marcus A Lawson; Caroline André; Eileen M Briley; Sandra S Szegedi; Jacques Lestage; Nathalie Castanon; Miles Herkenham; Robert Dantzer; Keith W Kelley
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Phenotypic characterization of regulatory T cells in the human decidua.

Authors:  J Heikkinen; M Möttönen; A Alanen; O Lassila
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 8.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Hepatitis E and pregnancy: understanding the pathogenesis.

Authors:  Udayakumar Navaneethan; Mayar Al Mohajer; Mohamed T Shata
Journal:  Liver Int       Date:  2008-07-25       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.